Published in Women's Health Weekly, November 10th, 2005
"Long-term endocrine therapy for breast cancer may have clinical implications as drugs that potentially alter the lipid profile may increase the risk of developing cardiovascular disease," investigators in Greece reported.
"In a companion subprotocol to the ATENA (Adjuvant post-Tamoxifen Exemestane versus Nothing Applied) trial," C. Markopoulos and colleagues "compared the effect of the steroidal aromatase inactivator exemestane on the lipid profile of post-menopausal women with operable breast...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly